Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04081220 · ClinicalTrials.gov registry record · Phase 2
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2
A Phase 2 study of Thrombocythemia, Essential, sponsored by The University of Texas Health Science Center at San Antonio.
- Active
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT04081220: Active Phase 2 study of Thrombocythemia, Essential, sponsored by The University of Texas Health Science Center at San Antonio.
NCT04081220 is a Phase 2 study of Thrombocythemia, Essential that is active but no longer recruiting, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04081220, a Phase 2 study of Thrombocythemia, Essential, is active but no longer recruiting, sponsored by The University of Texas Health Science Center at San Antonio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.
Primary Outcome
ELN criteria
Conditions Studied
Interventions
- DRUG IMG-7289
Study Locations (1)
Texas
- Mays Cancer Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-04-09 |
| Est. Completion | 2026-12-20 |
| Phase | Phase 2 |
What the registry record for NCT04081220 still lists
NCT04081220 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Thrombocythemia, Essential appearing as the primary indexed condition, and to 1 intervention - of which IMG-7289 is the first listed.
NCT04081220 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04081220 about?
NCT04081220 is a clinical study titled "Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2". This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.
What is the current status of trial NCT04081220?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2020-04-09. Estimated completion is 2026-12-20.
What conditions does trial NCT04081220 study?
This clinical trial studies the following conditions: Thrombocythemia, Essential.
What interventions are being tested in trial NCT04081220?
The interventions under investigation include: IMG-7289 (DRUG).
Who is sponsoring clinical trial NCT04081220?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04081220 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombocythemia, Essential
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04081220's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI